Patents by Inventor Bruce Kenneth Walcheck

Bruce Kenneth Walcheck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT IMMUNE CELLS, METHODS OF MAKING, AND METHODS OF USE
    Publication number: 20240124550
    Abstract: A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.
    Type: Application
    Filed: September 26, 2023
    Publication date: April 18, 2024
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Jianming Wu, Bruce Kenneth Walcheck, Robert Harrison Hullsiek, Yungfang Li, Hemant Kumar Mishra
  • Polypeptides, cells, and methods involving engineered CD16
    Patent number: 11370825
    Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: June 28, 2022
    Assignee: Regents of the University of Minnesota
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16
    Publication number: 20210332103
    Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Application
    Filed: April 19, 2021
    Publication date: October 28, 2021
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • RECOMBINANT IMMUNE CELLS, METHODS OF MAKING, AND METHODS OF USE
    Publication number: 20200283501
    Abstract: A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 10, 2020
    Inventors: Jianming Wu, Bruce Kenneth Walcheck, Robert Harrison Hullsiek, Yungfang Li, Hemant Kumar Mishra
  • POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16
    Publication number: 20200017570
    Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 16, 2020
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • Polypeptides, cells, and methods involving engineered CD16
    Patent number: 10464989
    Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: November 5, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16
    Publication number: 20170174743
    Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Application
    Filed: March 27, 2015
    Publication date: June 22, 2017
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Li